United States Endobronchial Ultrasound Biopsy Market Size and Forecast 2025–2033

The United States Endobronchial Ultrasound (EBUS) Biopsy Market is witnessing steady expansion as healthcare providers rapidly shift toward safer, minimally invasive diagnostic technologies. According to Renub Research, the U.S. EBUS biopsy market is projected to grow from US$ 246.82 billion in 2024 to US$ 356.2 billion by 2033, registering a CAGR of 4.16% between 2025 and 2033.

This growth is tied directly to the increasing prevalence of lung cancer, COPD, tuberculosis, and other respiratory diseases that require fast, accurate staging and diagnosis. As clinicians prioritize patient comfort and diagnostic accuracy, EBUS biopsy has become an essential part of modern respiratory care.

An Overview of the United States Endobronchial Ultrasound Biopsy Industry

Endobronchial ultrasound biopsy has become a cornerstone of lung disease diagnostics. It allows physicians to collect tissue or fluid samples from the lungs and surrounding lymph nodes using bronchoscopy combined with ultrasound imaging—eliminating the need for traditional surgical biopsies.

The technique is particularly valuable in diagnosing:

Lung cancer

Chronic Obstructive Pulmonary Disease (COPD)

Tuberculosis

Mediastinal lymph node metastasis

Granulomatous and infectious diseases

Unlike surgical mediastinoscopy, EBUS biopsy offers real-time imaging, lower complication rates, and shorter patient recovery times, making it a more patient-friendly approach.

Recent statistics reinforce the need for such diagnostic advancements:

According to the American Lung Association (2024), 11.7 million Americans—or 4.6% of adults—had a COPD diagnosis in 2022.

Adults aged 65 and older are significantly more affected, with nearly 7% diagnosed.

American Cancer Society (ACS) 2024 estimates that the U.S. will see 2 million new cancer cases, including 234,500 lung and bronchus cancer cases, marking a significant driver of biopsy demand.

These clinical trends underscore why EBUS biopsy is increasingly the preferred diagnostic pathway for pulmonologists and oncologists.

Key Growth Drivers of the United States EBUS Biopsy Market

1. Rising Prevalence of Lung Diseases

Respiratory diseases remain a major public health challenge in the U.S. Early and accurate diagnosis is crucial, especially in lung cancer cases where patient outcomes hinge on timely staging. With millions affected by COPD, lung cancer, and other chronic respiratory illnesses, the demand for precise, minimally invasive diagnostic procedures continues to increase.

EBUS biopsy stands out because:

It enables real-time visualization of lymph nodes.

It reduces diagnostic errors compared to blind biopsy techniques.

It helps determine the most effective treatment strategy.

As awareness grows among both patients and healthcare providers, the adoption of EBUS biopsy is expected to rise proportionately.

2. Advancements in Diagnostic Technologies

The shift toward AI-driven diagnostics, enhanced ultrasound processors, and improved probe sensitivity has transformed EBUS biopsy into a highly reliable diagnostic modality.

Key technological innovations include:

High-resolution ultrasound probes capable of accessing deep-seated lymph nodes

Advanced biopsy needles engineered for precise and safe sampling

Digital imaging systems integrated with AI for faster interpretation

Cloud-based diagnostic platforms that enhance collaboration across healthcare systems

These innovations are not only expanding the diagnostic capabilities of pulmonologists but are also streamlining workflows within hospitals and clinics, leading to better patient outcomes.

3. Growing Preference for Minimally Invasive Procedures

Healthcare delivery in the United States has strongly shifted toward patient-centric and minimally invasive care. EBUS biopsy perfectly aligns with this trend because it:

Requires only local anesthesia and light sedation

Minimizes pain, risk, and recovery time

Reduces hospital stays and procedural costs

Offers higher diagnostic accuracy than many conventional approaches

Hospitals and ambulatory surgical centers are increasingly incorporating EBUS systems, supported by reimbursement policies designed to encourage safer and more efficient diagnostic methods.

Challenges Impacting Market Growth

1. High Cost of Equipment and Procedures

EBUS biopsy equipment—including scopes, processors, and biopsy accessories—is technologically advanced and therefore expensive. Smaller hospitals and rural clinics often struggle with:

High capital investment

Maintenance and calibration costs

Limited reimbursement coverage in certain cases

Patient out-of-pocket expenses

These financial hurdles can restrict broader adoption across underserved regions.

2. Need for Skilled Medical Professionals

Performing EBUS biopsy requires:

In-depth training

Precision in lymph node navigation

Expertise in interpreting real-time ultrasound images

A shortage of trained pulmonologists in rural and semi-urban areas limits procedural availability. While training programs continue to expand, the steep learning curve remains a notable barrier to widespread adoption.

United States EBUS Biopsy Market — State-Level Analysis

The adoption of EBUS biopsy varies across the country, driven by differences in healthcare infrastructure, prevalence of respiratory diseases, and availability of trained specialists.

California

California leads the nation in EBUS adoption thanks to its robust healthcare network and high concentration of research institutions. Key contributors include:

A large patient base

Nationally recognized cancer centers

Strong investments in medical research and innovation

Extensive collaborations between hospitals and medtech companies

California remains a major hub for clinical trials and the development of next-generation EBUS technologies.

Texas

Texas is experiencing rapid adoption, supported by cities like Houston, Dallas, and Austin, which host some of the country's top cancer and respiratory care centers. The state benefits from:

A growing population with rising respiratory disease rates

Significant healthcare infrastructure investments

Strong medical education programs expanding EBUS expertise

Texas' business-friendly environment also helps attract manufacturers and innovators in diagnostic technology.

New York

New York is another major contributor to market expansion. The state’s world-class healthcare institutions, including leading cancer hospitals and academic research centers, provide a solid foundation for:

High procedural volume

Early adoption of innovative tools

Strong reimbursement and regulatory support

Strong collaboration between clinicians and technology developers

With rising respiratory disease incidence, demand for EBUS biopsy continues to accelerate in New York.

Florida

Florida’s large elderly population drives urgent need for fast, minimally invasive respiratory diagnostics. Key growth drivers include:

Increased COPD and lung cancer prevalence among seniors

Expanding hospital networks in Miami, Tampa, and Orlando

Clinical trial activity and technological adoption

State policies supporting advanced medical procedures

Florida is well-positioned to remain one of the fastest-growing EBUS biopsy markets in the United States.

Market Segmentation

By Product

EBUS Scopes

EBUS Needles

Ultrasound Processors & Imaging Systems

Accessories

By Application

Cancer Diagnostic

Infection Diagnostic

Others

By End Use

Hospitals

Ambulatory Surgical Centers (ASCs)

Specialty Clinics

By States

California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, New Jersey, Washington, North Carolina, Massachusetts, Virginia, Michigan, Maryland, Colorado, Tennessee, Indiana, Arizona, Minnesota, Wisconsin, Missouri, Connecticut, South Carolina, Oregon, Louisiana, Alabama, Kentucky, Rest of United States

Competitive Landscape

The U.S. EBUS biopsy market is competitive and technology-driven. Major players include:

GE Healthcare

Siemens Healthcare Private Limited

Koninklijke Philips N.V.

Boston Scientific Corporation

Olympus Corporation

Cook Group Incorporated

FUJIFILM Holdings Corporation

Medi-Globe Technologies GmbH

These companies are focusing on innovation, strategic partnerships, training programs, and product upgrades to enhance market presence.

Recent Developments

Introduction of AI-powered imaging tools enhancing real-time visualization

Development of robotic bronchoscopy platforms integrated with EBUS

Increased FDA approvals for advanced biopsy needles and imaging systems

Growing investments in U.S.-based manufacturing for improved supply chain resilience

SWOT Analysis

Strengths

Highly accurate, minimally invasive diagnostic method

Strong clinical adoption across oncology and pulmonology

Technological innovation improving outcomes

Weaknesses

High equipment and procedural cost

Steep learning curve for clinicians

Opportunities

Growing aging population

Integration of AI and robotics

Expansion in ambulatory surgical centers

Threats

Reimbursement inconsistencies

Shortage of trained specialists

Final Thoughts

The United States Endobronchial Ultrasound Biopsy Market is entering a crucial phase of growth driven by rising respiratory disease prevalence, ongoing technological advancements, and strong clinical preference for minimally invasive diagnostic solutions. With a projected increase to US$ 356.2 billion by 2033, the market is poised to become an essential pillar of the country’s respiratory care ecosystem.

As healthcare providers continue to prioritize accuracy, safety, and patient comfort, the demand for EBUS biopsy systems will remain strong. The next decade will likely see wider adoption across all states, deeper integration with AI and digital tools, and expanded use in early cancer detection and infectious disease management.